BOSTON, Massachusetts, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc. ("Radiance") announced today that it has signed an exclusive licensing agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited (iCareab's most important partner), for the joint development and commercialization of RB-164 (SYS6005), a novel clinical-stage antibody-drug conjugate (ADC) targeting ROR-1. Under the agreement, Radiance gains exclusive commercialization rights for RB-164 in the United States, Canada, the European Union, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, and Australia. CSPC maintains all rights to SYS6005 in all other global markets.For additional resources, click here.